Merck

Latest Stories

FILE - A JetBlue plane lands at Logan International Airport, Jan. 26, 2023, in Boston. JetBlue reports earnings on Tuesday, July 30, 2024. (AP Photo/Michael Dwyer, File)

Wall Street mostly higher on earnings ahead of Federal Reserve meeting

By Yuri Kageyama and Matt Ott - Associated Press

A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. Merck is suing the federal government Tuesday, June 6, 2023, over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion. The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. (AP Photo/Matt Rourke) **FILE**

Merck sues to stop Biden’s drug-negotiation program, calls it ‘extortion’

By Tom Howell Jr. - The Washington Times

A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. Merck is suing the federal government Tuesday, June 6, 2023, over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion. The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. (AP Photo/Matt Rourke) **FILE**

Merck sues federal government, calling plan to negotiate Medicare drug prices extortion

By Tom Murphy - Associated Press

A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. Moderna shares slipped Tuesday, April 11, 2023, after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial. (AP Photo/Bill Sikes) **FILE**

Moderna, Merck say vaccine-drug combo shows promise against melanoma

By Tom Howell Jr. - The Washington Times

A woman receives the Johnson & Johnson's Janssen COVID-19 vaccine at vaccination center located inside the National Theater in Prague, Czech Republic, on Nov. 11, 2021. The Czech Republic has recorded a significant decline in people dying of COVID-19 despite facing a record number of infected in one month. Over 560,000 new coronavirus were registered in the country in January, by far the most in one month since the beginning of the pandemic amid a record surge of infections driven by the highly contagious omicron variant. (AP Photo/Petr David Josek) **FILE**

J&J paused COVID-19 vaccine product at Dutch plant: Report

By Tom Howell Jr. - The Washington Times

This undated file image provided by Merck &amp; Co. shows their new antiviral medication molnupiravir. An experimental COVID-19 drug that could soon become the first U.S.-authorized pill to treat the coronavirus faces one final hurdle Tuesday: A panel of government experts will scrutinize data on the medication from drugmaker Merck. (Merck &amp; Co. via AP, File)

FDA panel narrowly backs COVID-19 pill from Merck

By Matthew Perrone - Associated Press

This undated image provided by Merck &amp; Co. shows their new antiviral medication. Pharmaceutical company Merck &amp; Co. said Friday, Oct. 1, 2021, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. (Merck &amp; Co. via AP) ** FILE **

FDA: Merck COVID-19 pill effective, experts will review safety

By Matthew Perrone - Associated Press

FILE - This undated file image provided by Merck &amp; Co. shows their new antiviral medication. The European Medicines Agency said it has received a request from Merck to authorize its coronavirus antiviral, the first pill shown to treat COVID-19. In a statement on Tuesday, Nov. 23, 2021, the EU drug regulator said it had started evaluating molnupiravir, made by Merck and Ridgeback Biotherapeutics and that a decision could be made within weeks on whether it might be cleared. (Merck &amp; Co. via AP, File)

Merck asks EU regulator to authorize its COVID-19 pill

Associated Press

In this undated file image provided by Merck & Co. shows their new antiviral medication. The pharmaceutical Merck has agreed to allow other drugmakers worldwide to make its COVID-19 treatment, the first pill that has been shown to be effective against the disease, in a move aimed at helping millions of people in poorer countries access to the drug. In a statement on Wednesday, Oct. 27, 2021, the U.N.-backed Medicines Patent Pool said it had signed a voluntary licensing agreement for molnupiravir with Merck and its partner Ridgeback Biotherapeutics. (Merck & Co. via AP, File)

U.K. authorizes Merck’s molnupiravir, first pill shown to treat COVID-19

By Matthew Perrone and Maria Cheng - Associated Press

What about Ivermectin, Fauci?

Nurse practitioners Taryn McCoy, left, and Gina LaFountain take inventory of supplies in the intensive care ward, one of four wards that are part of the 32-bed Samaritan's Purse Emergency Field Hospital set up in one of the University of Mississippi Medical Center's parking garages, Tuesday, Aug. 17, 2021, in Jackson, Miss. The field hospital joins a 20-bed field hospital and monoclonal antibody clinic opened by the U.S. Department of Health and Human Services at UMMC in response to the rising number of COVID-19 cases in the state. (AP Photo/Rogelio V. Solis) ** FILE **

Pack of pills, preventive antibodies add to arsenal of COVID-19 treatments

By Shen Wu Tan and Tom Howell Jr. - The Washington Times

This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. said Friday, Oct. 1, 2021, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the U.S. and around the world to authorize its use. (Merck & Co. via AP)

Merck sees promising results in trial of COVID-19 pill, will apply for emergency approval from FDA

By Tom Howell Jr. - The Washington Times

In this Dec. 18, 2014, file photo, a person walks through a Merck company building in Kenilworth, N.J. (AP Photo/Mel Evans, File) ** FILE **

Merck buying Acceleron Pharma in $11.5B deal

Associated Press

In this Dec. 18, 2014, file photo, a person walks through a Merck company building in Kenilworth, N.J. (AP Photo/Mel Evans, File) ** FILE **

U.S. purchases 1.7M courses of Merck’s COVID-19 pill ahead of approval

By Tom Howell Jr. - The Washington Times

In this Dec. 18, 2014, file photo, a person walks through a Merck company building in Kenilworth, N.J. (AP Photo/Mel Evans, File) ** FILE **

New era begins at Merck as pandemic cuts Q1 sales, profit

By LINDA A. JOHNSON - Associated Press

President Joe Biden speaks about efforts to combat COVID-19, in the State Dining Room of the White House, Tuesday, March 2, 2021, in Washington. (AP Photo/Evan Vucci)

Biden stands by May timeline for vaccines for all US adults

By ZEKE MILLER and LINDA A. JOHNSON and JONATHAN LEMIRE - Associated Press

Biden administration official: Merck to help produce rival Johnson & Johnson’s coronavirus vaccine t

Associated Press

FILE - This September 2020, file photo provided by Johnson &amp; Johnson shows a pharmacist preparing to give an experimental COVID-19 vaccine. The U.S. is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday, Feb. 27, 2021 cleared a Johnson &amp; Johnson shot that works with just one dose instead of two. (Johnson &amp; Johnson via AP, File)

Biden vows enough vaccine for all US adults by end of May

By ZEKE MILLER and LINDA A. JOHNSON and JONATHAN LEMIRE - Associated Press

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck posted a big fourth-quarter loss, mainly due to much higher spending on research, production and overhead, and announced longtime chief executive, Kenneth Frazier, will retire on July 1, 2021. (AP Photo/Seth Wenig, File)

Longtime Merck CEO, minority advocate Ken Frazier to retire

By LINDA A. JOHNSON - Associated Press

This May 1, 2018, photo shows Merck corporate headquarters in Kenilworth, N.J. The drugmaker will stop developing two potential COVID-19 vaccines after seeing poor results in early-stage studies. The company said Monday, Jan. 25, 2021, that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. (AP Photo/Seth Wenig) **FILE**

Merck ends development of two potential COVID-19 vaccines

By TOM MURPHY - Associated Press